A Real-World Evaluation of Risk Factors for Disease Progression in Patients with Polycythemia Vera (PV) Enrolled in REVEAL

医学 真性红细胞增多症 内科学 骨髓纤维化 骨髓增生性肿瘤 国际预后积分系统 单变量分析 骨髓 胃肠病学 骨髓增生异常综合症 多元分析
作者
Michael R. Grunwald,Jeffrey I. Zwicker,Aaron T. Gerds,John M. Burke,Zhenyi Xue,Erin L. Crowgey,Justine Carl,Patricia Feldman,Evan M. Braunstein,Stephen T. Oh
出处
期刊:Blood [Elsevier BV]
卷期号:142 (Supplement 1): 385-385
标识
DOI:10.1182/blood-2023-180215
摘要

Background: PV is a myeloproliferative neoplasm complicated by symptom burden, splenomegaly, vascular events, and disease progression to myelofibrosis (MF). Current risk models for PV include advanced age and history of thrombotic events (TEs), yet information on risk factors for PV progression is limited. In this analysis, we assessed the rate of PV progression to MF during the P rospective Obs ervational Study of Patients With Polycythemia Vera in US Clinic al Practices Trial (REVEAL) and assessed baseline demographics and disease characteristics as risk factors for PV progression. Methods: Criteria for enrollment in REVEAL included a physician-reported PV diagnosis. PV progression was defined by meeting any of the following criteria during the study: 1) Death from MF/myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML); 2) new/worsening splenomegaly, plus 2 of the following criteria: white blood cell (WBC) count >11×10 9/L, platelets (PLT) <100×10 9/L, hemoglobin (Hb) <10 g/dL; 3) evidence of progression to MF from bone marrow (BM) biopsy; 4) new/worsening splenomegaly, plus blasts >1%. Univariate and multivariate logistic regressions were performed to assess risk factors of PV progression. Results: Of the 2510 patients enrolled in REVEAL, 1191 (47.5%) were reported to have a JAK2 mutation at enrollment. To confirm PV diagnosis, digital droplet PCR for JAK2 p.V617F was performed on all patients with the first available biospecimen from an optional biological specimen substudy; 1520/1871 (81.2%) were positive. A further 367 patients with a physician-reported JAK2 mutation and 135 with a PV diagnosis confirmed by BM aspirate/biopsy were included; 488 patients (19.4%) who did not meet any criteria were excluded. Of the 2022 patients with confirmed diagnosis, median (range) follow-up was 44.1 (0-59.5) months; 134 (6.6%) progressed to MF (BM evidence of MF, n=69 [3.4%]; new/worsening splenomegaly, plus 2 of the following criteria WBC count >11×10 9/L, PLT <100×10 9/L, Hb <10 g/dL, n=44 [2.2%]; new/worsening splenomegaly, plus blasts >1%, n=37 [1.8%]; death from MF/MDS/AML, n=22 [1.1%]). A nonsignificant trend toward higher mean JAK2 p.V617F variant allele frequency was observed in patients with vs without progression (Table 1). Compared with patients without progression to MF, patients with progression were of similar age (69.5 vs 68.0 y) and had a longer time from PV diagnosis to enrollment (median, 7.2 vs 3.7 y; P<0.0001; Table 1). The percentage of patients with vs without progression enrolled via academic practices was 23.1% vs 16.9%; the percentage of patients with vs without progression who had no cytoreductive treatment prior to enrollment was 85.1% vs 91.2%. PV risk stratification (age >60 y or history of TEs) at enrollment was similar for patients with vs without progression (high risk, 61.9% vs 63.5%). However, a higher percentage of patients with vs without progression had a history of TEs at enrollment (29.9% vs 19.7%; P=0.0050). Univariate analysis also identified hematocrit (HCT) ≤0.45 L/L (63.9% vs 53.5%; P=0.0288) and WBC count >11×10 9/L (50.4% vs 31.8%; P<0.0001) at enrollment as significantly different between patients with vs without progression, respectively (Figure 1). In univariate analyses, time from PV diagnosis, TE history, HCT ≤0.45 L/L, WBC count >11×10 9/L at enrollment were each associated with increased PV progression risk (Figure 1). These factors were retained as significant covariates in multivariate analyses with stepwise model selection (OR [90% CI]: time from PV diagnosis to enrollment, 1.030 [1.016-1.044], P<0.0001; history of TEs at enrollment, 1.96 [1.281-2.998], P=0.0019; HCT >0.45 vs ≤0.45 L/L, 0.637 [0.421-0.964], P=0.0330; WBC >11 vs ≤11×10 9/L, 2.205 [1.477-3.292], P<0.0001). Conclusions: This real-world analysis of prospective data from REVEAL found that 6.6% of patients with PV progressed to MF over the median 44.1 months of follow-up. Time from diagnosis to enrollment and history of TEs were each significantly associated with an increased risk of PV progression; the latter finding regarding TE history was unexpected and represents a potentially novel risk factor for PV progression. HCT ≤0.45 L/L and WBC >11×10 9/L at enrollment were also significantly associated with an increased progression risk. Additional analysis is ongoing to better understand the causal relationships between these risk factors and PV progression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
satori完成签到,获得积分10
刚刚
刚刚
zhaojian完成签到,获得积分20
刚刚
刚刚
1秒前
芋圆完成签到,获得积分10
1秒前
嘚嘚嘚发布了新的文献求助10
1秒前
夜雨完成签到,获得积分10
1秒前
江海下百川完成签到,获得积分10
1秒前
量子星尘发布了新的文献求助10
2秒前
WANG.完成签到,获得积分10
3秒前
kaiX完成签到,获得积分10
3秒前
3秒前
在水一方应助菲菲呀采纳,获得10
3秒前
3秒前
认真初南发布了新的文献求助10
3秒前
Tina完成签到,获得积分10
3秒前
4秒前
一周发布了新的文献求助10
4秒前
ZJ完成签到,获得积分10
5秒前
幸福大白发布了新的文献求助10
5秒前
453完成签到,获得积分10
5秒前
江南完成签到,获得积分10
5秒前
毛头侠完成签到,获得积分10
5秒前
爱听歌康乃馨完成签到,获得积分0
5秒前
我真服了完成签到 ,获得积分10
5秒前
腾飞发布了新的文献求助10
6秒前
科研通AI6应助princekin采纳,获得10
7秒前
852应助自然的诗翠采纳,获得10
7秒前
Ehgnix完成签到,获得积分10
7秒前
平常致远发布了新的文献求助30
7秒前
zh完成签到,获得积分10
7秒前
哦哦哦完成签到 ,获得积分10
7秒前
ZBY发布了新的文献求助10
7秒前
7秒前
Sara发布了新的文献求助10
8秒前
猫南北完成签到,获得积分10
8秒前
fyj发布了新的文献求助30
8秒前
8秒前
慕子默完成签到,获得积分10
9秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
网络安全 SEMI 标准 ( SEMI E187, SEMI E188 and SEMI E191.) 1000
计划经济时代的工厂管理与工人状况(1949-1966)——以郑州市国营工厂为例 500
INQUIRY-BASED PEDAGOGY TO SUPPORT STEM LEARNING AND 21ST CENTURY SKILLS: PREPARING NEW TEACHERS TO IMPLEMENT PROJECT AND PROBLEM-BASED LEARNING 500
Why America Can't Retrench (And How it Might) 400
Two New β-Class Milbemycins from Streptomyces bingchenggensis: Fermentation, Isolation, Structure Elucidation and Biological Properties 300
Modern Britain, 1750 to the Present (第2版) 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 催化作用 遗传学 冶金 电极 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 4614444
求助须知:如何正确求助?哪些是违规求助? 4018649
关于积分的说明 12439260
捐赠科研通 3701425
什么是DOI,文献DOI怎么找? 2041187
邀请新用户注册赠送积分活动 1073927
科研通“疑难数据库(出版商)”最低求助积分说明 957600